Printer Friendly

The Perrigo Company awarded FDA approval to market mint flavoured mini nicotine lozenges USP, 2mg & 4mg.

M2 PHARMA-October 11, 2012-The Perrigo Company awarded FDA approval to market mint flavoured mini nicotine lozenges USP, 2mg & 4mg(C)2012 M2 COMMUNICATIONS

Healthcare supplier The Perrigo Company (Nasdaq:PRGO)(Nasdaq:TASE) revealed on Wednesday the receipt of approval for its Abbreviated New Drug Applications (ANDA) to market over-the-counter nicotine polacrilex mini lozenge USP, 2mg (mint flavor) and 4mg (mint flavor).

The US Food and Drug Administration (FDA) approval of this ANDA, reportedly marks the first approval for mini lozenge products that will be targeted for the store brand market. The product is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking.

This mint flavoured mini nicotine lozenges USP, 2mg & 4mg is expected to be launched in the next 90 days.

According to the company, the mint flavored mini lozenge will be marketed under retailer and wholesalers' store, or own brand labels and is comparable to GlaxoSmithKline's Nicorette Mini Lozenge, which is selling at an annual rate estimated at over USD30m at all retail outlets.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 11, 2012
Words:179
Previous Article:Cleveland BioLabs Inc partners with Incuron LLC to commence Phase 1 trial of CBL0137 for oncology applications.
Next Article:Raptor Pharmaceutical Corp acquires cysteamine intellectual property for tissue fibrotic disease.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters